Trials / Terminated
TerminatedNCT04131634
Stereotactic Ablative Radiation for Oligo-Progression of Urothelial Cancer
A Phase II Trial of Stereotactic Ablative Radiation (SAbR) for Urothelial Cancer Patients With Progression While on Anti-PD-1/PD-L1 Immunotherapy
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 2 (actual)
- Sponsor
- University of Texas Southwestern Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the benefit of SAbR for oligo-progressive metastatic urothelial cancer.
Detailed description
Oligo-progressive urothelial cancer with limited disease burden and progression on an anti-PD-1/L1 immune checkpoint inhibitor.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | Stereotactic Ablative Radiation | A stereotactic relocalization system that relies upon stereoscopic radiographs, implanted fiducials, or near real-time CT based verification will be used.Investigators will have the discretion to choose from biologically equivalent dose levels using 1, 3 or 5 fractions. All active lesions need to be addressed by local therapy |
Timeline
- Start date
- 2020-01-16
- Primary completion
- 2020-12-17
- Completion
- 2021-06-10
- First posted
- 2019-10-18
- Last updated
- 2021-06-16
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT04131634. Inclusion in this directory is not an endorsement.